Jianerkang Medical 健尔康
2 significant filings since 31 May 2026: 1 on dividend and 1 on management change. The latest, on 2 Jul 2026: 2025年年度权益分派实施公告.
自 31 May 2026 起有 2 份重大公告：dividend 1 份、management change 1 份。最新一份（2 Jul 2026）：2025年年度权益分派实施公告。
As of 25 Sep 2026 截至2026年9月25日
Jianerkang Medical is a medical devices company listed on the Shanghai Stock Exchange on 7 Nov 2024. The company reported lower revenue and profit in 2025 compared to 2024, with revenue at RMB1.02bn and attributable net profit at RMB111.4m, down 2.0% and 7.3% respectively. Margins and returns remained stable, with a 24.8% gross margin, 10.9% net margin, and 7.7% ROE in 2025. Operating cash flow per share was RMB1.02, ahead of net profit, with a cash flow to profit ratio of 1.42x. As of 30 Jun 2026, the company had a strong balance sheet, with a current ratio of 5.67 and liabilities to assets at 14.8%. The first half of 2026 showed revenue growth of 5.8% and net profit growth of 4.8%. The actual controller is 陈国平, who held 43.43% as of 30 Jun 2026.
健尔康是一家医疗器械公司，于2024年11月7日在上海证券交易所上市。公司2025年营业收入为10.24亿元，归母净利润为1.11亿元，较2024年分别下降2.0%和7.3%。2025年毛利率为24.8%，净利率为10.9%，净资产收益率为7.7%，盈利水平稳定。每股经营现金流为1.02元，经营现金流与净利润之比为1.42倍，现金生成能力优于利润。截至2026年6月30日，公司资产负债率为14.8%，流动比率5.67，速动比率4.74，短期偿债能力较强。2026年上半年营业收入同比增长5.8%，归母净利润同比增长4.8%。实际控制人为陈国平，2026年6月30日持股43.43%。
- Revenue growth in the full year 2026 compared to 2025
2026全年营业收入较2025年的同比变化 - Attributable net profit trend in the full year 2026
2026全年归母净利润变动趋势 - Operating cash flow per share in the full year 2026
2026全年每股经营现金流 - Liabilities to assets ratio as of 31 Dec 2026
2026年12月30日资产负债率 - Change in net profit excluding non-recurring items for 2026
2026年扣除非经常性损益后的净利润同比变化 - Next shareholder distribution announcement
下一次股东分红公告
- Company: Jianerkang Medical 健尔康, Shanghai Stock Exchange 603205; industry Medical Devices; listed 7 Nov 2024.
公司：健尔康，上海证券交易所 603205；行业：医疗器械；上市日期：2024年11月7日。 - Close on 24 Sep 2026 RMB21.57; close on 24 Sep 2025 RMB28.42, RMB28.08 in today's terms; one-year change, adjusted for distributions and share changes -23.2%.
2026年9月24日收盘价21.57元；2025年9月24日收盘价28.42元（前复权28.08元）；一年涨跌幅（复权）-23.2%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB19.87 to RMB29.02.
52周区间（前复权）19.87元至29.02元。 - Market capitalisation RMB3.37bn; P/E TTM 29.6; price to book 2.23x.
总市值33.65亿元；市盈率（TTM）29.6；市净率2.23倍。 - Revenue 2025 RMB1.02bn; 2024 RMB1.05bn; change -2.0%.
营业收入2025年10.24亿元；2024年10.46亿元；同比-2.0%。 - Attributable net profit 2025 RMB111.4m; 2024 RMB120.2m; change -7.3%.
归属于母公司股东的净利润2025年1.11亿元；2024年1.20亿元；同比-7.3%。 - Net profit excluding non-recurring items, 2025 change -6.0%.
2025年扣除非经常性损益后的净利润同比-6.0%。 - Basic EPS 2025 RMB0.71; 2024 RMB0.97.
基本每股收益2025年0.71元；2024年0.97元。 - Operating cash flow per share 2025 RMB1.02; 2024 RMB1.18; operating cash flow to net profit 1.42x.
每股经营现金流2025年1.02元；2024年1.18元；经营现金流与净利润之比1.42倍。 - 2025 gross margin 24.8%; net margin 10.9%; ROE 7.7%.
2025年毛利率24.8%；净利率10.9%；净资产收益率7.7%。 - At 30 Jun 2026: liabilities to assets 14.8%; current ratio 5.67; quick ratio 4.74; receivable days 81; inventory days 90.
截至2026年6月30日：资产负债率14.8%；流动比率5.67；速动比率4.74；应收账款周转天数81；存货周转天数90。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB493.2m, change +5.8%; attributable net profit RMB50.5m, change +4.8%; operating cash flow per share RMB0.59.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入4.93亿元，同比+5.8%；归母净利润5,046.2万元，同比+4.8%；每股经营现金流0.59元。 - Ownership: actual controller 陈国平; largest holder at 30 Jun 2026: 陈国平, 43.43%.
股权：实际控制人：陈国平；2026年6月30日第一大股东：陈国平，持股43.43%。 - Latest distribution: ex-date 9 Jul 2026, cash RMB0.25 per share.
最近一次分配：除权除息日2026年7月9日，每股现金0.25元。 - Aurelian Grade C, score 60.5 of 100, graded within a peer group of 140 companies in its industry; no rank among peers is given.
金源评级C，得分60.5（满分100），于行业同业140家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。